CompletedPhase 2NCT00606008

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Edward Pan, M.D., r.ph
H. Lee Moffitt Cancer Center and Research Institute
Intervention
Sunitinib Malate(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20072012

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00606008 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials